Prelamin A prenylation and the treatment of progeria

Journal of Lipid Research

Volumn 51, Issue 2, 2010, Pages 223-225

  Worman, Howard J ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAMIN A; LAMIN C; PRELAMIN A; PROGERIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; NUCLEAR PROTEIN; PROTEIN PRECURSOR;

ALTERNATIVE RNA SPLICING; AUTOSOMAL DOMINANT DISORDER; CARBOXY TERMINAL SEQUENCE; CATALYSIS; DISEASE MODEL; DRUG ACTIVITY; DRUG MECHANISM; EXON; FIBROBLAST; GENE MUTATION; HUMAN; NONHUMAN; NOTE; PATHOPHYSIOLOGY; PHENOTYPE; PREMATURE AGING; PRENYLATION; PRIORITY JOURNAL; PROGERIA; PROTEIN EXPRESSION; ANIMAL; CHILD; DRUG EFFECT; METABOLISM; MOUSE; PROTEIN PRENYLATION;

ANIMALS; CHILD; HUMANS; MICE; NUCLEAR PROTEINS; PROGERIA; PROTEIN PRECURSORS; PROTEIN PRENYLATION;

EID: 77949498915     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.E004366     Document Type: Note

References (21)

1. Merideth, M. A., L. B. Gordon, S. Clauss, V. Sachdev, A. C. Smith, M. B. Perry, C. C. Brewer, C. Zalewski, H. J. Kim, B. Solomon, et al. 2008. Phenotype and course of Hutchinson-Gilford progeria syndrome. N. Engl. J. Med. 358: 592-604. (Pubitemid 351214286)
2. Eriksson, M., W. T. Brown, L. B. Gordon, M. W. Glynn, J. Singer, L. Scott, M. R. Erdos, C. M. Robbins, T. Y. Moses, P. Berglund, et al. 2003. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature. 423: 293-298. (Pubitemid 40852699)
3. De Sandre-Giovannoli, A., R. Bernard, P. Cau, C. Navarro, J. Amiel, I. Boccaccio, S. Lyonnet, C. L. Stewart, A. Munnich, M. Le Merrer, et al. 2003. Lamin a truncation in Hutchinson-Gilford progeria. Science. 300: 2055. (Pubitemid 36760124)
4. Worman, H. J., and G. Bonne. 2007. " Laminopathies ": a wide spectrum of human diseases. Exp. Cell Res. 313: 2121-2133. (Pubitemid 46850729)
5. Lin, F., and H. J. Worman. 1993. Structural organization of the human gene encoding nuclear lamin A and nuclear lamin C. J. Biol. Chem. 268: 16321-16326. (Pubitemid 23229934)
6. Young, S. G., L. G. Fong, and S. Michaelis. 2005. Prelamin A, Zmpste24, misshapen cell nuclei, and progeria-new evidence suggesting that protein farnesylation could be important for disease pathogenesis. J. Lipid Res. 46: 2531-2558. (Pubitemid 43107466)
7. Rusiñol, A. E., and M. S. Sinensky. 2006. Farnesylated lamins, prog-eroid syndromes and farnesyl transferase inhibitors. J. Cell Sci. 119: 3265-3272.
8. Bergo, M. O., B. Gavino, J. Ross, W. K. Schmidt, C. Hong, L. V. Kendall, A. Mohr, M. Meta, H. Genant, Y. Jiang, et al. 2002. Zmpste24 defi ciency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. Proc. Natl. Acad. Sci. USA. 99: 13049-13054.
9. Pendás, A. M., Z. Zhou, J. Cadiñanos, J. M. Freije, J. Wang, K. Hultenby, A. Astudillo, A. Wernerson, F. Rodríguez, K. Tryggvason, et al. 2002. Defective prelamin A processing and muscular and ad-ipocyte alterations in Zmpste24 metalloproteinase-defi cient mice. Nat. Genet. 31: 94-99.
10. Fong, L. G., J. K. Ng, M. Meta, N. Coté, S. H. Yang, C. L. Stewart, T. Sullivan, A. Burghardt, S. Majumdar, K. Reue, et al. 2004. Heterozygosity for Lmna defi ciency eliminates the progeria-like phenotypes in Zmpste24-defi cient mice. Proc. Natl. Acad. Sci. USA. 101: 18111-18116. (Pubitemid 40054082)
11. Yang, S. H., M. O. Bergo, J. I. Toth, X. Qiao, Y. Hu, S. Sandoval, M. Meta, P. Bendale, M. H. Gelb, S. G. Young, et al. 2005. Blocking protein farnesyltransferase improves nuclear blebbing in mouse fi broblasts with a targeted Hutchinson-Gilford progeria syndrome mutation. Proc. Natl. Acad. Sci. USA. 102: 10291-10296. (Pubitemid 41023365)
12. Yang, S. H., M. Meta, X. Qiao, D. Frost, J. Bauch, C. Coffi nier, S. Majumdar, M. O. Bergo, S. G. Young, and L. G. Fong. 2006. Treatment with a proteinfarnesyltransferase inhibitor improves disease phenotypes in mice with a targeted Hutchinson-Gilford prog-eria syndrome mutation. J. Clin. Invest. 116: 2115-2121.
13. Toth, J. I., S. H. Yang, X. Qiao, A. P. Beigneux, M. H. Gelb, C. L. Moulson, J. H. Miner, S. G. Young, and L. G. Fong. 2005. Blocking protein farnesyltransferase improves nuclear shape in fi broblasts from humans with progeroid syndromes. Proc. Natl. Acad. Sci. USA. 102: 12873-12878.
14. Capell, B. C., M. R. Erdos, J. P. Madigan, J. J. Fiordalisi, R. Varga, K. N. Conneely, L. B. Gordon, C. J. Der, A. D. Cox, and F. S. Collins. 2005. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc. Natl. Acad. Sci. USA. 102: 12879-12884.
15. Glynn, M. W., and T. W. Glover. 2005. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition. Hum. Mol. Genet. 14: 2959-2969.
16. Fong, L. G., D. Frost, M. Meta, X. Qiao, S. H. Yang, C. Coffi nier, and S. G. Young. 2006. A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science. 311: 1621-1623.
17. Capell, B. C., M. Olive, M. R. Erdos, K. Cao, D. A. Faddah, U. L. Tavarez, K. N. Conneely, X. Qu, H. San, S. K. Ganesh, et al. 2008. A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model. Proc. Natl. Acad. Sci. USA. 105: 15902-15907.
18. Yang, S. H., D. A. Andres, H. P. Spielmann, S. G. Young, and L. G. Fong. 2008. Progerin elicits disease phenotypes of progeria in mice whether or not it is farnesylated. J. Clin. Invest. 118: 3291-3300.
19. Yang, S. H., S. Y. Chang, D. A. Andres, H. P. Spielmann, S. G. Young, and L. G. Fong. 2010. Assessing the effi cacy of protein farnesyltransferase inhibitors in mouse models of progeria. J. Lipid Res. 51: 400-405.
20. Gordon, L. B., C. J. Harling-Berg, and F. G. Rothman. 2007. Highlights of the 2007 Progeria Research Foundation scientifi c workshop: progress in translational science. J. Gerontol. A Biol. Sci. Med. Sci. 63: 777-787.
21. Varela, I., S. Pereira, A. P. Ugalde, C. L. Navarro, M. F. Suárez, P. Cau, J. Cadiñanos, F. G. Osorio, N. Foray, J. Cobo, et al. 2008. Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat. Med. 14: 767-772.